ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $138.03M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 2.68M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +65.98% |
| Volume | 11,234 |
| Open | 51.26 |
| Previous Close | 52.06 |
| Day's Range | 51.08 - 51.74 |
| 52-Week Low | 22.33 |
| 52-Week High | 54.79 |
| Beta | 0.85 |
| Holdings | 92 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
30.47% of assets| Name | Symbol | Weight |
|---|---|---|
| Kymera Therapeutics, Inc. | KYMR | 4.66% |
| Celcuity Inc. | CELC | 3.34% |
| Alkermes plc | ALKS | 3.21% |
| CG Oncology, Inc. | CGON | 3.06% |
| Mirum Pharmaceuticals, Inc. | MIRM | 3.06% |
| Amicus Therapeutics, Inc. | FOLD | 2.86% |
| ACADIA Pharmaceuticals Inc. | ACAD | 2.68% |
| NewAmsterdam Pharma Company N.V. | NAMS | 2.60% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 2.52% |
| Apogee Therapeutics, Inc. | APGE | 2.48% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.17346 | Dec 26, 2024 |
| Dec 21, 2023 | $0.07106 | Dec 27, 2023 |
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
News
This Biotech ETF Is a Catalyst-Rich Story
Biotechnology stocks and the related ETFs bounced back in significant fashion last year. There's been some cooling of that trend to start 2026, but that could be just the opportunity some investors ha...
Biotech M&A Wave Positions SBIO for Growth
The biotech M&A market is heating up as pharmaceutical companies confront a looming patent cliff that will strip $200 billion to $250 billion in branded medicine sales by 2032, according to an ING rep...
SBIO: A Shock Biotech Winner In 2025
The ALPS Medical Breakthroughs ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness. SBIO benefited from a rebound in FDA drug approvals, pos...
Sabio Holdings Inc. (SBIO:CA) Q3 2025 Earnings Call Transcript
Sabio Holdings Inc. ( SBIO:CA) Q3 2025 Earnings Call November 25, 2025 10:00 AM EST Company Participants Aziz Rahimtoola - Co-Founder, CEO & Chairman Sajid Premji - Chief Financial Officer Conference...
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
SBIO ETF: Betting On Medical Breakthroughs
ALPS Medical Breakthroughs ETF is rated Hold due to high fees, low yield, and mixed performance compared to other healthcare ETFs. The SBIO ETF focuses on small and mid-cap biotech companies with drug...
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symb...
Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange
Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users ...
